The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study
© 2021 International Society of Nephrology. Published by Elsevier Inc..
BACKGROUND: Soluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not been evaluated across diverse types of kidney diseases.
METHODS: We measured these plasma biomarkers in 523 individuals enrolled into a prospective, observational cohort study of patients undergoing clinically indicated native kidney biopsy at 3 tertiary care hospitals. Two kidney pathologists adjudicated biopsy specimens for semiquantitative scores of histopathology. Proportional hazard models tested associations between biomarkers and risks of kidney disease progression (composite of ≥40% estimated glomerular filtration rate [eGFR] decline or end-stage kidney disease [ESKD]) and death.
RESULTS: Mean eGFR was 56.4±36 ml/min per 1.73 m2 and the median proteinuria (interquartile range) was 1.6 (0.4, 3.9) g/g creatinine. The most common primary clinicopathologic diagnoses were proliferative glomerulonephritis (29.2%), nonproliferative glomerulopathy (18.1%), advanced glomerulosclerosis (11.3%), and diabetic kidney disease (11.1%). sTNFR-1, sTNFR-2, MCP-1, and suPAR were associated with tubulointerstitial and glomerular lesions. YKL-40 was not associated with any histopathologic lesions after multivariable adjustment. During a median follow-up of 65 months, 182 participants suffered kidney disease progression and 85 participants died. After multivariable adjustment, each doubling of sTNFR-1, sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of kidney disease progression, with hazard ratios ranging from 1.21 to 1.47. Each doubling of sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of death, with hazard ratios ranging from 1.33 to 1.45. suPAR was not significantly associated with kidney disease progression or death.
CONCLUSIONS: sTNFR-1, sTNFR-2, YKL-40, MCP-1, and suPAR are associated with underlying histopathologic lesions and adverse clinical outcomes across a diverse set of kidney diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
---|---|
Enthalten in: |
Kidney international reports - 6(2021), 3 vom: 20. März, Seite 685-694 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Srivastava, Anand [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarker |
---|
Anmerkungen: |
Date Revised 21.04.2022 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.ekir.2020.12.025 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322895634 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322895634 | ||
003 | DE-627 | ||
005 | 20231225183018.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.ekir.2020.12.025 |2 doi | |
028 | 5 | 2 | |a pubmed24n1076.xml |
035 | |a (DE-627)NLM322895634 | ||
035 | |a (NLM)33732983 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Srivastava, Anand |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Associations of Plasma Biomarkers of Inflammation With Histopathologic Lesions, Kidney Disease Progression, and Mortality-The Boston Kidney Biopsy Cohort Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 21.04.2022 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a © 2021 International Society of Nephrology. Published by Elsevier Inc. | ||
520 | |a BACKGROUND: Soluble tumor necrosis factor receptor (sTNFR)-1, sTNFR-2, YKL-40, monocyte chemoattractant protein (MCP)-1, and soluble urokinase plasminogen activator receptor (suPAR) have emerged as promising biomarkers of inflammation but have not been evaluated across diverse types of kidney diseases | ||
520 | |a METHODS: We measured these plasma biomarkers in 523 individuals enrolled into a prospective, observational cohort study of patients undergoing clinically indicated native kidney biopsy at 3 tertiary care hospitals. Two kidney pathologists adjudicated biopsy specimens for semiquantitative scores of histopathology. Proportional hazard models tested associations between biomarkers and risks of kidney disease progression (composite of ≥40% estimated glomerular filtration rate [eGFR] decline or end-stage kidney disease [ESKD]) and death | ||
520 | |a RESULTS: Mean eGFR was 56.4±36 ml/min per 1.73 m2 and the median proteinuria (interquartile range) was 1.6 (0.4, 3.9) g/g creatinine. The most common primary clinicopathologic diagnoses were proliferative glomerulonephritis (29.2%), nonproliferative glomerulopathy (18.1%), advanced glomerulosclerosis (11.3%), and diabetic kidney disease (11.1%). sTNFR-1, sTNFR-2, MCP-1, and suPAR were associated with tubulointerstitial and glomerular lesions. YKL-40 was not associated with any histopathologic lesions after multivariable adjustment. During a median follow-up of 65 months, 182 participants suffered kidney disease progression and 85 participants died. After multivariable adjustment, each doubling of sTNFR-1, sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of kidney disease progression, with hazard ratios ranging from 1.21 to 1.47. Each doubling of sTNFR-2, YKL-40, and MCP-1 was associated with increased risks of death, with hazard ratios ranging from 1.33 to 1.45. suPAR was not significantly associated with kidney disease progression or death | ||
520 | |a CONCLUSIONS: sTNFR-1, sTNFR-2, YKL-40, MCP-1, and suPAR are associated with underlying histopathologic lesions and adverse clinical outcomes across a diverse set of kidney diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biomarker | |
650 | 4 | |a fibrosis | |
650 | 4 | |a histopathology | |
650 | 4 | |a inflammation | |
650 | 4 | |a kidney biopsy | |
650 | 4 | |a kidney disease | |
700 | 1 | |a Schmidt, Insa M |e verfasserin |4 aut | |
700 | 1 | |a Palsson, Ragnar |e verfasserin |4 aut | |
700 | 1 | |a Weins, Astrid |e verfasserin |4 aut | |
700 | 1 | |a Bonventre, Joseph V |e verfasserin |4 aut | |
700 | 1 | |a Sabbisetti, Venkata |e verfasserin |4 aut | |
700 | 1 | |a Stillman, Isaac E |e verfasserin |4 aut | |
700 | 1 | |a Rennke, Helmut G |e verfasserin |4 aut | |
700 | 1 | |a Waikar, Sushrut S |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 6(2021), 3 vom: 20. März, Seite 685-694 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
773 | 1 | 8 | |g volume:6 |g year:2021 |g number:3 |g day:20 |g month:03 |g pages:685-694 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2020.12.025 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 6 |j 2021 |e 3 |b 20 |c 03 |h 685-694 |